Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer.

This recommendation is largely based on an exploratory analysis of the MOSAIC trial which showed an absolute 7% increase in the probability of DFS at 5 years with the oxaliplatin-containing regimen, though it did not reach statistical significance [ 67 , 78 ].

also in 111,027 other papers